ALXO net incomeQ2 2026-$17.97M
ALXO net income was -$17.97M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$25.95M a year earlier. For the full fiscal 2025 it was -$101.69M, compared with -$134.85M in fiscal 2024.
ALX Oncology Holdings Inc. (ALXO) financials
For the twelve months ended Jun 30, 2026, ALX Oncology Holdings Inc. reported -$80.89M of net income.
- Net income, TTM
- -$80.89M
- Free cash flow, TTM
- -$70.95M
- EPS, diluted, TTM
- -$1.13
- Cash
- $22.69M
- Total debt
- $9.71M
- Market cap
- $160.5M
FY2018FY2022
FY2018FY2025
FY2018FY2025
ALXO revenue and earnings growth
ALXO EPSQ2 2026-$0.13
ALXO diluted EPS was -$0.13 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.90, compared with -$2.58 in fiscal 2024.
ALXO free cash flowQ2 2026-$16.07M
ALXO free cash flow was -$16.07M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$23.45M a year earlier. For the full fiscal 2025 it was -$84.35M, compared with -$122.36M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $0 | $0 | $1.18M | $4.80M | $2.07M |
| Research and development | $77.00M | $116.37M | $141.79M | $98.40M | $60.17M | $28.96M | $16.31M | $11.27M |
| Selling, general and admin | $23.85M | $26.09M | $28.48M | $29.04M | $23.39M | $14.81M | $3.31M | $2.60M |
| Operating income | -$104.02M | -$142.47M | -$170.28M | -$127.44M | -$83.56M | -$43.66M | -$19.18M | -$13.68M |
| Interest expense | $1.60M | $1.73M | $1.56M | $238.0K | $13.0K | - | - | - |
| Pre-tax income | -$101.69M | -$134.85M | -$160.81M | -$123.42M | -$83.48M | -$45.50M | -$19.21M | -$13.69M |
| Income tax | $0 | $0 | $0 | $64.0K | -$21.0K | $241.0K | $34.0K | $45.0K |
| Net income | -$101.69M | -$134.85M | -$160.81M | -$123.48M | -$83.46M | -$45.74M | -$19.24M | -$13.73M |
| EPS, basic | -$1.90 | -$2.58 | -$3.74 | -$3.03 | -$2.07 | -$2.76 | -$7.56 | -$6.33 |
| EPS, diluted | -$1.90 | -$2.58 | -$3.74 | -$3.03 | -$2.07 | -$2.76 | -$7.56 | -$6.33 |
| Diluted shares | 53.7M | 52.2M | 43.0M | 40.7M | 40.3M | 18.5M | 3.1M | 2.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $16.37M | $17.63M | $22.41M | $48.89M | $363.67M | $434.22M | $9.02M | $8.26M |
| Short-term investments | $28.42M | $110.19M | $160.33M | $217.38M | - | - | - | - |
| Current assets | $50.73M | $134.35M | $188.66M | $270.97M | $367.02M | $435.99M | $9.81M | - |
| Total assets | $59.05M | $147.78M | $242.55M | $306.49M | $380.18M | $436.05M | $10.68M | - |
| Current liabilities | $24.55M | $18.50M | $36.00M | $28.32M | $15.29M | $6.20M | $4.98M | - |
| Short-term debt | $5.22M | $435.0K | $0 | $0 | - | - | - | - |
| Long-term debt | $4.53M | $9.47M | $9.64M | $9.39M | - | - | $5.42M | - |
| Total debt | $9.75M | $9.90M | $9.64M | $9.39M | - | - | $5.42M | - |
| Total liabilities | $33.06M | $34.16M | $52.84M | $43.02M | $17.13M | $6.21M | $10.95M | - |
| Shareholders' equity | $25.98M | $113.62M | $189.71M | $263.46M | $363.05M | $429.85M | -$70.64M | -$51.78M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$84.14M | -$121.91M | -$130.36M | -$89.22M | -$68.10M | -$38.29M | -$14.25M | -$13.19M |
| Capital expenditures | $212.0K | $447.0K | $1.27M | $1.43M | $666.0K | $31.0K | $353.0K | $653.0K |
| Free cash flow | -$84.35M | -$122.36M | -$131.64M | -$90.65M | -$68.77M | -$38.32M | -$14.60M | -$13.84M |
| Investing cash flow | $82.59M | $86.26M | $44.66M | -$235.42M | -$4.92M | $610.0K | -$353.0K | -$653.0K |
| Financing cash flow | $362.0K | $30.82M | $59.29M | $9.86M | $2.47M | $462.88M | $15.36M | $1.0K |
| Share repurchases | - | - | - | - | - | - | - | $6.0K |
| Stock-based compensation | $12.58M | $27.09M | $26.27M | $23.84M | $13.91M | $5.44M | $297.0K | $269.0K |
| Depreciation and amortization | $706.0K | $872.0K | $836.0K | $342.0K | $51.0K | $202.0K | $429.0K | $431.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | -100.0% | -75.4% | 132.0% | - |
| Operating margin | - | - | - | - | - | -3694.0% | -400.0% | -662.0% |
| Net margin | - | - | - | - | - | -3869.7% | -401.2% | -664.3% |
| Free cash flow margin | - | - | - | - | - | -3242.0% | -304.5% | -669.7% |
| Return on equity | -391.4% | -118.7% | -84.8% | -46.9% | -23.0% | -10.6% | - | - |
| Return on assets | -172.2% | -91.3% | -66.3% | -40.3% | -22.0% | -10.5% | -180.2% | - |
| Current ratio | 2.07 | 7.26 | 5.24 | 9.57 | 24.00 | 70.28 | 1.97 | - |
| Debt to equity | 0.38 | 0.09 | 0.05 | 0.04 | - | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $13.14M | $13.61M | $17.64M | $17.44M | $18.02M | $23.89M | $23.53M | $26.47M | $34.65M | $31.72M | $41.78M | $45.77M |
| Selling, general and admin | $5.13M | $5.36M | $5.38M | $5.09M | $5.45M | $7.93M | $7.08M | $6.10M | $6.87M | $6.04M | $6.24M | $7.51M |
| Operating income | -$18.03M | -$18.97M | -$23.02M | -$22.53M | -$26.65M | -$31.82M | -$30.61M | -$32.57M | -$41.52M | -$37.76M | -$48.02M | -$53.27M |
| Interest expense | $285.0K | $331.0K | $383.0K | $408.0K | $405.0K | $406.0K | $427.0K | $446.0K | $429.0K | $427.0K | $415.0K | $391.0K |
| Net income | -$17.97M | -$17.93M | -$22.85M | -$22.14M | -$25.95M | -$30.75M | -$29.16M | -$30.71M | -$39.40M | -$35.58M | -$45.47M | -$50.99M |
| EPS, basic | -$0.13 | -$0.17 | -$0.42 | -$0.41 | -$0.49 | -$0.58 | -$0.53 | -$0.58 | -$0.76 | -$0.71 | -$0.92 | -$1.24 |
| EPS, diluted | -$0.13 | -$0.17 | -$0.42 | -$0.41 | -$0.49 | -$0.58 | -$0.53 | -$0.58 | -$0.76 | -$0.71 | -$0.92 | -$1.24 |
| Diluted shares | 135.6M | 104.6M | - | 53.6M | 53.4M | 53.4M | - | 52.7M | 51.8M | 50.1M | - | 41.1M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $22.69M | $32.28M | $16.37M | $23.44M | $19.30M | $20.61M | $17.63M | $16.10M | $15.53M | $14.04M | $22.41M | $19.58M |
| Short-term investments | $115.54M | $108.04M | $28.42M | $37.18M | $60.01M | $77.22M | $110.19M | $132.47M | $141.19M | $143.40M | $160.33M | $170.43M |
| Current assets | $143.46M | $145.56M | $50.73M | $66.52M | $85.26M | $102.53M | $134.35M | $155.90M | $168.71M | $167.86M | $188.66M | $199.07M |
| Total assets | $160.82M | $178.33M | $59.05M | $82.72M | $95.32M | $120.90M | $147.78M | $185.72M | $214.62M | $212.65M | $242.55M | $220.11M |
| Current liabilities | $14.78M | $20.18M | $24.55M | $27.72M | $18.85M | $18.74M | $18.50M | $32.34M | $38.45M | $32.23M | $36.00M | $35.14M |
| Short-term debt | $0 | $5.22M | $5.22M | $4.35M | $3.04M | $1.74M | $435.0K | $0 | $0 | $0 | $0 | $0 |
| Long-term debt | $9.71M | $3.29M | $4.53M | $5.76M | $7.00M | $8.23M | $9.47M | $9.84M | $9.77M | $9.70M | $9.64M | $9.57M |
| Total debt | $9.71M | $8.51M | $9.75M | $10.11M | $10.04M | $9.97M | $9.90M | $9.84M | $9.77M | $9.70M | $9.64M | $9.57M |
| Total liabilities | $24.63M | $26.98M | $33.06M | $37.92M | $30.91M | $32.60M | $34.16M | $48.91M | $55.30M | $48.45M | $52.84M | $51.35M |
| Shareholders' equity | $136.19M | $151.35M | $25.98M | $44.80M | $64.42M | $88.30M | $113.62M | $136.81M | $159.32M | $164.19M | $189.71M | $168.75M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.06M | -$18.65M | -$18.98M | -$17.09M | -$23.41M | -$24.66M | -$32.05M | -$25.38M | -$26.57M | -$37.92M | -$39.68M | -$31.16M |
| Capital expenditures | $17.0K | $50.0K | $49.0K | $56.0K | $47.0K | $60.0K | $60.0K | $149.0K | $90.0K | $148.0K | $148.0K | -$1.30M |
| Free cash flow | -$16.07M | -$18.70M | -$19.03M | -$17.15M | -$23.45M | -$24.72M | -$32.11M | -$25.52M | -$26.66M | -$38.07M | -$39.83M | -$32.46M |
| Investing cash flow | $6.52M | -$105.04M | $11.23M | $21.39M | $22.32M | $27.64M | $33.18M | $25.69M | $907.0K | $26.47M | -$16.67M | $12.81M |
| Financing cash flow | $137.0K | $139.59M | $678.0K | -$159.0K | -$222.0K | $65.0K | $328.0K | $251.0K | $27.15M | $3.09M | $59.17M | -$111.0K |
| Stock-based compensation | $2.68M | $2.51M | $2.71M | $2.52M | $2.14M | $5.22M | $5.86M | $6.95M | $7.25M | $7.03M | $6.72M | $6.96M |
| Depreciation and amortization | $100.0K | $150.0K | $151.0K | $200.0K | $200.0K | $211.0K | $214.0K | $200.0K | $200.0K | $214.0K | $207.0K | $200.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 9.71 | 7.21 | 2.07 | 2.40 | 4.52 | 5.47 | 7.26 | 4.82 | 4.39 | 5.21 | 5.24 | 5.66 |
| Debt to equity | 0.07 | 0.06 | 0.38 | 0.23 | 0.16 | 0.11 | 0.09 | 0.07 | 0.06 | 0.06 | 0.05 | 0.06 |
Source: XBRL data ALX Oncology Holdings Inc. files with the SEC, latest filing dated Aug 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ALXO peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ALXO | - | - | -$80.89M | - | $160.5M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
ALXO FAQ
6 questionsIs ALXO profitable?
No. ALX Oncology Holdings Inc. reported a net loss of $80.89M for the twelve months ended Jun 30, 2026.How much cash and debt does ALXO have?
ALX Oncology Holdings Inc. reported $22.69M in cash and cash equivalents and $9.71M of debt on its most recent balance sheet in SEC filings.What is ALXO free cash flow?
ALX Oncology Holdings Inc. generated -$70.95M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$70.78M less capital expenditures.What is ALXO earnings per share?
Diluted earnings per share were -$1.13 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did ALXO last report financial results?
The latest statements here come from ALX Oncology Holdings Inc.'s 10-Q filed on Aug 6, 2026, covering the period ended Jun 30, 2026.Where does this ALXO financial data come from?
Quantisnow builds these statements from the structured XBRL data ALX Oncology Holdings Inc. files with the SEC. It is provided for information only and is not investment advice.